123K-share equity grant to Lucid Diagnostics (LUCD) director Debra White vests 2029

Rhea-AI Filing Summary

White Debra reported acquisition or exercise transactions in this Form 4 filing.

Lucid Diagnostics Inc. director Debra White reported receiving a grant of 123,000 shares of common stock as a restricted stock award under the company’s 2018 Equity Plan. The award was granted at $0.00 per share and increases her directly held stake to 235,800 shares after the transaction.

The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning she must remain in service through that date for the shares to fully vest.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider White Debra

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	123,000	$0.00	--

Holdings After Transaction: Common Stock — 235,800 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

White Debra

(Last) (First) (Middle)

360 MADISON AVENUE

25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		A		123,000(1)	A	$0	235,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

	/s/ Michael A. Gordon, by power of attorney	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lucid Diagnostics (LUCD) director Debra White report on this Form 4?

Debra White reported receiving a grant of 123,000 shares of Lucid Diagnostics common stock as restricted stock. The award was granted at $0.00 per share under the 2018 Equity Plan, increasing her directly held ownership to 235,800 shares after the transaction.

Is the 123,000-share grant to Debra White at Lucid Diagnostics (LUCD) fully vested?

No, the 123,000-share grant is restricted stock with a single vesting date of May 20, 2029. The shares are subject to forfeiture if the required service period is not completed, so vesting depends on continued service through that date.

What type of transaction is reported for Lucid Diagnostics (LUCD) on this Form 4?

The Form 4 reports an acquisition coded as a grant, award, or other acquisition of non-derivative common stock. It reflects an equity compensation grant rather than an open-market purchase or sale, with the shares issued at a price of $0.00 per share.

How many Lucid Diagnostics (LUCD) shares does Debra White own after the reported grant?

After the restricted stock award, Debra White directly owns 235,800 shares of Lucid Diagnostics common stock. This total includes the newly granted 123,000 restricted shares, which will vest on May 20, 2029, subject to completion of the required service period.

Under which plan was Debra White’s Lucid Diagnostics (LUCD) stock grant made?

The 123,000-share restricted stock grant to Debra White was made under Lucid Diagnostics’ 2018 Equity Plan. This plan provides for equity-based awards to eligible participants, with this particular grant carrying a single vesting date of May 20, 2029 and forfeiture conditions.